This subject phenotype table contains subject ID, patient's cohort and age, living status during last assessment, gender, number of prior therapies, clinical benefit, tumor location and largest dimension, biopsy type, primary melanoma type, ipilimumab dose, drug treatment, response duration, serum lactate dehydrogenase, BRAF (GeneID: 673) or NRAS (GeneID: 4893) gene mutations, overall survival, and biopsy status before and after treatment.

pht005208
Beskrivning

pht005208

Alias
UMLS CUI [1,1]
C3846158
De-identified Subject ID
Beskrivning

SUBJECT_ID

Datatyp

string

Alias
UMLS CUI [1,1]
C4684638
UMLS CUI [1,2]
C2348585
Patient's cohort in current study
Beskrivning

Cohort

Datatyp

string

Alias
UMLS CUI [1,1]
C0599755
UMLS CUI [1,2]
C0008972
Patient's age
Beskrivning

Age

Datatyp

text

Måttenheter
  • years
Alias
UMLS CUI [1,1]
C0001779
years
Alive during last assessment
Beskrivning

Alive

Datatyp

text

Måttenheter
  • Yes/No/Not Available
Alias
UMLS CUI [1,1]
C2584946
UMLS CUI [1,2]
C0679830
Gender of participant
Beskrivning

Sex

Datatyp

text

Alias
UMLS CUI [1,1]
C0079399
Number of prior therapies (cytotoxic or IL-2)
Beskrivning

Priors

Datatyp

text

Måttenheter
  • 0,1,2,3,YES
Alias
UMLS CUI [1,1]
C0449788
UMLS CUI [1,2]
C0332152
UMLS CUI [1,3]
C0087111
UMLS CUI [1,4]
C0304497
UMLS CUI [1,5]
C0199975
0,1,2,3,YES
Long time clinical benefit
Beskrivning

Clinical_Benefit

Datatyp

text

Alias
UMLS CUI [1,1]
C0443252
UMLS CUI [1,2]
C4684590
Location of tumor in study
Beskrivning

Site

Datatyp

string

Alias
UMLS CUI [1,1]
C0450429
UMLS CUI [1,2]
C0027651
Largest dimension of tumor
Beskrivning

Largest Dimension (cm)

Datatyp

text

Alias
UMLS CUI [1,1]
C2919402
Biopsy type
Beskrivning

Biopsy type

Datatyp

string

Alias
UMLS CUI [1,1]
C0005558
UMLS CUI [1,2]
C4744818
Primary melanoma type
Beskrivning

Primary Melanoma type

Datatyp

string

Alias
UMLS CUI [1,1]
C1306459
UMLS CUI [1,2]
C0025202
UMLS CUI [1,3]
C4744818
Ipilimumab dose
Beskrivning

Ipi_dosing

Datatyp

text

Måttenheter
  • mg/kg x no. dose
Alias
UMLS CUI [1,1]
C1367202
UMLS CUI [1,2]
C0178602
mg/kg x no. dose
Drug of treatment
Beskrivning

Drug

Datatyp

string

Alias
UMLS CUI [1,1]
C0013227
Response duration in weeks
Beskrivning

Response duration (weeks)

Datatyp

text

Alias
UMLS CUI [1,1]
C0871261
UMLS CUI [1,2]
C1948053
UMLS CUI [1,3]
C0439230
Serum lactate dehydrogenase
Beskrivning

LDH (normal less than 246)

Datatyp

text

Måttenheter
  • IU/L
Alias
UMLS CUI [1,1]
C0202113
IU/L
BRAF(GeneID: 673)/NRAS(GeneID: 4893) mutations
Beskrivning

BRAF/NRAS status

Datatyp

string

Alias
UMLS CUI [1,1]
C0205309
UMLS CUI [1,2]
C0026882
UMLS CUI [1,3]
C0809246
UMLS CUI [1,4]
C0812241
Overall survival
Beskrivning

OS_yr

Datatyp

text

Måttenheter
  • years
Alias
UMLS CUI [1,1]
C4086681
years
Biopsy status before and after Ipilimumab treatment
Beskrivning

Biopsy pre or post ipi

Datatyp

text

Alias
UMLS CUI [1,1]
C0005558
UMLS CUI [1,2]
C0449438
UMLS CUI [1,3]
C0332152
UMLS CUI [1,4]
C1367202
UMLS CUI [1,5]
C0087111
UMLS CUI [2,1]
C0005558
UMLS CUI [2,2]
C0449438
UMLS CUI [2,3]
C0231290
UMLS CUI [2,4]
C1367202
UMLS CUI [2,5]
C0087111

Similar models

This subject phenotype table contains subject ID, patient's cohort and age, living status during last assessment, gender, number of prior therapies, clinical benefit, tumor location and largest dimension, biopsy type, primary melanoma type, ipilimumab dose, drug treatment, response duration, serum lactate dehydrogenase, BRAF (GeneID: 673) or NRAS (GeneID: 4893) gene mutations, overall survival, and biopsy status before and after treatment.

Name
Typ
Description | Question | Decode (Coded Value)
Datatyp
Alias
Item Group
pht005208
C3846158 (UMLS CUI [1,1])
SUBJECT_ID
Item
De-identified Subject ID
string
C4684638 (UMLS CUI [1,1])
C2348585 (UMLS CUI [1,2])
Cohort
Item
Patient's cohort in current study
string
C0599755 (UMLS CUI [1,1])
C0008972 (UMLS CUI [1,2])
Age
Item
Patient's age
text
C0001779 (UMLS CUI [1,1])
Item
Alive during last assessment
text
C2584946 (UMLS CUI [1,1])
C0679830 (UMLS CUI [1,2])
Code List
Alive during last assessment
CL Item
Not available (Not available)
CL Item
Alive (Y)
Item
Gender of participant
text
C0079399 (UMLS CUI [1,1])
Code List
Gender of participant
CL Item
Female (F)
C0086287 (UMLS CUI [1,1])
CL Item
Male (M)
C0086582 (UMLS CUI [1,1])
Priors
Item
Number of prior therapies (cytotoxic or IL-2)
text
C0449788 (UMLS CUI [1,1])
C0332152 (UMLS CUI [1,2])
C0087111 (UMLS CUI [1,3])
C0304497 (UMLS CUI [1,4])
C0199975 (UMLS CUI [1,5])
Item
Long time clinical benefit
text
C0443252 (UMLS CUI [1,1])
C4684590 (UMLS CUI [1,2])
Code List
Long time clinical benefit
CL Item
Long time clinical benefits (LB)
CL Item
No long time clinical benefits (NB)
Site
Item
Location of tumor in study
string
C0450429 (UMLS CUI [1,1])
C0027651 (UMLS CUI [1,2])
Largest Dimension (cm)
Item
Largest dimension of tumor
text
C2919402 (UMLS CUI [1,1])
Biopsy type
Item
Biopsy type
string
C0005558 (UMLS CUI [1,1])
C4744818 (UMLS CUI [1,2])
Primary Melanoma type
Item
Primary melanoma type
string
C1306459 (UMLS CUI [1,1])
C0025202 (UMLS CUI [1,2])
C4744818 (UMLS CUI [1,3])
Ipi_dosing
Item
Ipilimumab dose
text
C1367202 (UMLS CUI [1,1])
C0178602 (UMLS CUI [1,2])
Drug
Item
Drug of treatment
string
C0013227 (UMLS CUI [1,1])
Response duration (weeks)
Item
Response duration in weeks
text
C0871261 (UMLS CUI [1,1])
C1948053 (UMLS CUI [1,2])
C0439230 (UMLS CUI [1,3])
LDH (normal less than 246)
Item
Serum lactate dehydrogenase
text
C0202113 (UMLS CUI [1,1])
BRAF/NRAS status
Item
BRAF(GeneID: 673)/NRAS(GeneID: 4893) mutations
string
C0205309 (UMLS CUI [1,1])
C0026882 (UMLS CUI [1,2])
C0809246 (UMLS CUI [1,3])
C0812241 (UMLS CUI [1,4])
OS_yr
Item
Overall survival
text
C4086681 (UMLS CUI [1,1])
Item
Biopsy status before and after Ipilimumab treatment
text
C0005558 (UMLS CUI [1,1])
C0449438 (UMLS CUI [1,2])
C0332152 (UMLS CUI [1,3])
C1367202 (UMLS CUI [1,4])
C0087111 (UMLS CUI [1,5])
C0005558 (UMLS CUI [2,1])
C0449438 (UMLS CUI [2,2])
C0231290 (UMLS CUI [2,3])
C1367202 (UMLS CUI [2,4])
C0087111 (UMLS CUI [2,5])
Code List
Biopsy status before and after Ipilimumab treatment
CL Item
post Ipilimumab treatment (post)
CL Item
pre Ipilimumab treatment (pre)